Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176

1.

Pillars Article: Cyclosporin A Specifically Inhibits Function of Nuclear Proteins Involved in T Cell Activation. Science. 1989. 246: 1617-1620.

Emmel EA, Verweij CL, Durand DB, Higgins KM, Lacy E, Crabtree GR.

J Immunol. 2018 Dec 1;201(11):3149-3152. No abstract available.

PMID:
30455370
2.

A multi-parameter response prediction model for rituximab in rheumatoid arthritis.

de Jong TD, Sellam J, Agca R, Vosslamber S, Witte BI, Tsang-A-Sjoe M, Mantel E, Bijlsma JW, Voskuyl AE, Nurmohamed MT, Verweij CL, Mariette X.

Joint Bone Spine. 2018 Mar;85(2):219-226. doi: 10.1016/j.jbspin.2017.02.015. Epub 2017 Mar 28.

PMID:
28363827
3.

Type I interferon response gene expression in established rheumatoid arthritis is not associated with clinical parameters.

de Jong TD, Blits M, de Ridder S, Vosslamber S, Wolbink G, Nurmohamed MT, Verweij CL.

Arthritis Res Ther. 2016 Dec 12;18(1):290.

4.

Changes in peripheral blood lymphocyte subsets during arthritis development in arthralgia patients.

Lübbers J, van Beers-Tas MH, Vosslamber S, Turk SA, de Ridder S, Mantel E, Wesseling JG, Reijm M, van Hoogstraten IM, Bijlsma JW, van Schaardenburg D, Bontkes HJ, Verweij CL.

Arthritis Res Ther. 2016 Sep 14;18(1):205. doi: 10.1186/s13075-016-1102-2.

5.

The type I interferon signature in leukocyte subsets from peripheral blood of patients with early arthritis: a major contribution by granulocytes.

de Jong TD, Lübbers J, Turk S, Vosslamber S, Mantel E, Bontkes HJ, van der Laken CJ, Bijlsma JW, van Schaardenburg D, Verweij CL.

Arthritis Res Ther. 2016 Jul 13;18:165. doi: 10.1186/s13075-016-1065-3.

6.

Autoantibody Specificities and Type I Interferon Pathway Activation in Idiopathic Inflammatory Myopathies.

Ekholm L, Vosslamber S, Tjärnlund A, de Jong TD, Betteridge Z, McHugh N, Plestilova L, Klein M, Padyukov L, Voskuyl AE, Bultink IE, Michiel Pegtel D, Mavragani CP, Crow MK, Vencovsky J, Lundberg IE, Verweij CL.

Scand J Immunol. 2016 Aug;84(2):100-9. doi: 10.1111/sji.12449.

7.

Physiological evidence for diversification of IFNα- and IFNβ-mediated response programs in different autoimmune diseases.

de Jong TD, Vosslamber S, Mantel E, de Ridder S, Wesseling JG, van der Pouw Kraan TC, Leurs C, Hegen H, Deisenhammer F, Killestein J, Lundberg IE, Vencovsky J, Nurmohamed MT, van Schaardenburg D, Bultink IE, Voskuyl AE, Pegtel DM, van der Laken CJ, Bijlsma JW, Verweij CL.

Arthritis Res Ther. 2016 Feb 17;18:49. doi: 10.1186/s13075-016-0946-9.

8.

B cell signature contributes to the prediction of RA development in patients with arthralgia.

Lübbers J, Vosslamber S, van de Stadt LA, van Beers-Tas M, Wesseling JG, von Blomberg BM, Witte BI, Bontkes HJ, van Schaardenburg D, Verweij CL.

Ann Rheum Dis. 2015 Sep;74(9):1786-8. doi: 10.1136/annrheumdis-2015-207324. Epub 2015 May 27. No abstract available.

PMID:
26019192
9.

Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab.

de Jong TD, Vosslamber S, Blits M, Wolbink G, Nurmohamed MT, van der Laken CJ, Jansen G, Voskuyl AE, Verweij CL.

Arthritis Res Ther. 2015 Mar 23;17:78. doi: 10.1186/s13075-015-0564-y.

10.

Arming the Melanoma Sentinel Lymph Node through Local Administration of CpG-B and GM-CSF: Recruitment and Activation of BDCA3/CD141(+) Dendritic Cells and Enhanced Cross-Presentation.

Sluijter BJ, van den Hout MF, Koster BD, van Leeuwen PA, Schneiders FL, van de Ven R, Molenkamp BG, Vosslamber S, Verweij CL, van den Tol MP, van den Eertwegh AJ, Scheper RJ, de Gruijl TD.

Cancer Immunol Res. 2015 May;3(5):495-505. doi: 10.1158/2326-6066.CIR-14-0165. Epub 2015 Jan 29.

11.

Moving towards personalized medicine in rheumatoid arthritis.

de Jong TD, Vosslamber S, Verweij CL.

Arthritis Res Ther. 2014;16(3):110.

12.

Gene expression analysis in RA: towards personalized medicine.

Burska AN, Roget K, Blits M, Soto Gomez L, van de Loo F, Hazelwood LD, Verweij CL, Rowe A, Goulielmos GN, van Baarsen LG, Ponchel F.

Pharmacogenomics J. 2014 Apr;14(2):93-106. doi: 10.1038/tpj.2013.48. Epub 2014 Mar 4. Review.

13.

Sex differences in the human peripheral blood transcriptome.

Jansen R, Batista S, Brooks AI, Tischfield JA, Willemsen G, van Grootheest G, Hottenga JJ, Milaneschi Y, Mbarek H, Madar V, Peyrot W, Vink JM, Verweij CL, de Geus EJ, Smit JH, Wright FA, Sullivan PF, Boomsma DI, Penninx BW.

BMC Genomics. 2014 Jan 17;15:33. doi: 10.1186/1471-2164-15-33.

14.

Using biomarkers to predict progression from clinically isolated syndrome to multiple sclerosis.

Tossberg JT, Crooke PS, Henderson MA, Sriram S, Mrelashvili D, Vosslamber S, Verweij CL, Olsen NJ, Aune TM.

J Clin Bioinforma. 2013 Oct 3;3(1):18. doi: 10.1186/2043-9113-3-18.

15.

Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis.

Blits M, Jansen G, Assaraf YG, van de Wiel MA, Lems WF, Nurmohamed MT, van Schaardenburg D, Voskuyl AE, Wolbink GJ, Vosslamber S, Verweij CL.

Arthritis Rheum. 2013 Nov;65(11):2791-802. doi: 10.1002/art.38094.

16.

The type I IFN signature as a biomarker of preclinical rheumatoid arthritis.

Lübbers J, Brink M, van de Stadt LA, Vosslamber S, Wesseling JG, van Schaardenburg D, Rantapää-Dahlqvist S, Verweij CL.

Ann Rheum Dis. 2013 May;72(5):776-80. doi: 10.1136/annrheumdis-2012-202753. Epub 2013 Feb 23.

PMID:
23434571
18.

Research highlights: Clinical relevance of the type I interferon signature in multiple sclerosis.

Verweij CL.

Pharmacogenomics. 2012 Dec;13(16):1883-5. doi: 10.2217/pgs.12.166. No abstract available.

PMID:
23215880
19.

The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients.

Raterman HG, Vosslamber S, de Ridder S, Nurmohamed MT, Lems WF, Boers M, van de Wiel M, Dijkmans BA, Verweij CL, Voskuyl AE.

Arthritis Res Ther. 2012 Apr 27;14(2):R95. doi: 10.1186/ar3819.

20.
21.

Gene-expression signatures: biomarkers toward diagnosing multiple sclerosis.

Tossberg JT, Crooke PS, Henderson MA, Sriram S, Mrelashvili D, Chitnis S, Polman C, Vosslamber S, Verweij CL, Olsen NJ, Aune TM.

Genes Immun. 2012 Feb;13(2):146-54. doi: 10.1038/gene.2011.66. Epub 2011 Sep 22.

22.

Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies.

Miossec P, Verweij CL, Klareskog L, Pitzalis C, Barton A, Lekkerkerker F, Reiter S, Laslop A, Breedveld F, Abadie E, Flamion B, Dere W, Mpofu S, Goel N, Ethgen D, Mitlak B, Ormarsdóttir S, Rao R, Tsouderos Y, Reginster JY; Group for Respect of Ethics and Excellence in Science (GREES).

Ann Rheum Dis. 2011 Oct;70(10):1713-8. doi: 10.1136/ard.2011.154252. Epub 2011 Jul 22. Review.

23.

Combining DNA-microarray data in systemic lupus erythematosus.

Verweij CL, Vosslamber S.

Genome Med. 2011 May 31;3(5):30. doi: 10.1186/gm246.

24.

Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in multiple sclerosis.

Vosslamber S, van der Voort LF, van den Elskamp IJ, Heijmans R, Aubin C, Uitdehaag BM, Crusius JB, van der Pouw Kraan TC, Comabella M, Montalban X, Hafler DA, De Jager PL, Killestein J, Polman CH, Verweij CL.

Genes Immun. 2011 Sep;12(6):466-72. doi: 10.1038/gene.2011.18. Epub 2011 Apr 7. Erratum in: Genes Immun. 2012 Jul, 13(5):443. van der PouwKraan, T C T M [corrected to van der Pouw Kraan, TCTM].

PMID:
21471993
25.

Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis.

Vosslamber S, Raterman HG, van der Pouw Kraan TC, Schreurs MW, von Blomberg BM, Nurmohamed MT, Lems WF, Dijkmans BA, Voskuyl AE, Verweij CL.

Ann Rheum Dis. 2011 Jun;70(6):1153-9. doi: 10.1136/ard.2010.147199. Epub 2011 Mar 27.

PMID:
21444302
26.

Pharmacogenetics: Anti-TNF therapy in RA--towards personalized medicine?

Verweij CL.

Nat Rev Rheumatol. 2011 Mar;7(3):136-8. doi: 10.1038/nrrheum.2011.13. Epub 2011 Feb 8.

PMID:
21304506
27.

Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients.

Thurlings RM, Boumans M, Tekstra J, van Roon JA, Vos K, van Westing DM, van Baarsen LG, Bos C, Kirou KA, Gerlag DM, Crow MK, Bijlsma JW, Verweij CL, Tak PP.

Arthritis Rheum. 2010 Dec;62(12):3607-14. doi: 10.1002/art.27702.

28.

Pharmacogenomics of infliximab treatment using peripheral blood cells of patients with rheumatoid arthritis.

van Baarsen LG, Wijbrandts CA, Gerlag DM, Rustenburg F, van der Pouw Kraan TC, Dijkmans BA, Tak PP, Verweij CL.

Genes Immun. 2010 Dec;11(8):622-9. doi: 10.1038/gene.2010.34. Epub 2010 Jun 17.

PMID:
20555356
29.

Synovial tissue heterogeneity in rheumatoid arthritis in relation to disease activity and biomarkers in peripheral blood.

van Baarsen LG, Wijbrandts CA, Timmer TC, van der Pouw Kraan TC, Tak PP, Verweij CL.

Arthritis Rheum. 2010 Jun;62(6):1602-7. doi: 10.1002/art.27415.

30.

Gene expression profiling in autoantibody-positive patients with arthralgia predicts development of arthritis.

van Baarsen LG, Bos WH, Rustenburg F, van der Pouw Kraan TC, Wolbink GJ, Dijkmans BA, van Schaardenburg D, Verweij CL.

Arthritis Rheum. 2010 Mar;62(3):694-704. doi: 10.1002/art.27294.

31.

Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment.

van Baarsen LG, Wijbrandts CA, Rustenburg F, Cantaert T, van der Pouw Kraan TC, Baeten DL, Dijkmans BA, Tak PP, Verweij CL.

Arthritis Res Ther. 2010;12(1):R11. doi: 10.1186/ar2912. Epub 2010 Jan 22.

32.

Transcript profiling towards personalised medicine in rheumatoid arthritis.

Verweij CL.

Neth J Med. 2009 Dec;67(11):364-71. Review.

33.

Type I interferons have no major influence on humoral autoimmunity in rheumatoid arthritis.

Cantaert T, van Baarsen LG, Wijbrandts CA, Thurlings RM, van de Sande MG, Bos C, van der Pouw Kraan TC, Verweij CL, Tak PP, Baeten DL.

Rheumatology (Oxford). 2010 Jan;49(1):156-66. doi: 10.1093/rheumatology/kep345. Epub 2009 Nov 23. Erratum in: Rheumatology (Oxford). 2014 Apr;53(4):770. van der Pouw, Tineke Kraan [corrected to van der Pouw Kraan, Tineke C T M].

PMID:
19933783
34.

Predicting the future of anti-tumor necrosis factor therapy.

Verweij CL.

Arthritis Res Ther. 2009;11(3):115. doi: 10.1186/ar2724. Epub 2009 Jun 22.

35.

Loss of imprinting of IGF2 characterises high IGF2 mRNA-expressing type of fibroblast-like synoviocytes in rheumatoid arthritis.

Martin-Trujillo A, van Rietschoten JG, Timmer TC, Rodríguez FM, Huizinga TW, Tak PP, Marsal S, Ibrahim SM, Dijkmans BA, van der Pouw Kraan TC, Verweij CL.

Ann Rheum Dis. 2010 Jun;69(6):1239-42. doi: 10.1136/ard.2008.106195. Epub 2009 Jun 24.

PMID:
19556211
36.

Transcription profiling of rheumatic diseases.

van Baarsen LG, Bos CL, van der Pouw Kraan TC, Verweij CL.

Arthritis Res Ther. 2009;11(1):207. doi: 10.1186/ar2557. Epub 2009 Jan 30. Review.

37.

Molecular subtypes of systemic sclerosis in association with anti-centromere antibodies and digital ulcers.

Bos CL, van Baarsen LG, Timmer TC, Overbeek MJ, Basoski NM, Rustenburg F, Baggen JM, Thiesen HJ, Dijkmans BA, van der Pouw Kraan TC, Voskuyl AE, Verweij CL.

Genes Immun. 2009 Apr;10(3):210-8. doi: 10.1038/gene.2008.98. Epub 2009 Jan 8.

PMID:
19129850
38.

Pharmacogenomics of IFN-beta in multiple sclerosis: towards a personalized medicine approach.

Vosslamber S, van Baarsen LG, Verweij CL.

Pharmacogenomics. 2009 Jan;10(1):97-108. doi: 10.2217/14622416.10.1.97. Review.

PMID:
19102719
39.

Epigenetic regulation and nucleosome positioning in the human TATA-less IL-1 alpha promoter.

van Rietschoten JG, Gal-Yam EN, Jeong S, Cortez CC, Verweij CL, Jones PA.

Genes Immun. 2008 Oct;9(7):582-90. doi: 10.1038/gene.2008.53. Epub 2008 Jul 10.

PMID:
18615092
40.

B lymphocyte autoimmunity in rheumatoid synovitis is independent of ectopic lymphoid neogenesis.

Cantaert T, Kolln J, Timmer T, van der Pouw Kraan TC, Vandooren B, Thurlings RM, Cañete JD, Catrina AI, Out T, Verweij CL, Zhang Y, Tak PP, Baeten D.

J Immunol. 2008 Jul 1;181(1):785-94.

41.

Synovial lymphoid neogenesis does not define a specific clinical rheumatoid arthritis phenotype.

Thurlings RM, Wijbrandts CA, Mebius RE, Cantaert T, Dinant HJ, van der Pouw-Kraan TC, Verweij CL, Baeten D, Tak PP.

Arthritis Rheum. 2008 Jun;58(6):1582-9. doi: 10.1002/art.23505.

42.

Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients.

van Baarsen LG, Vosslamber S, Tijssen M, Baggen JM, van der Voort LF, Killestein J, van der Pouw Kraan TC, Polman CH, Verweij CL.

PLoS One. 2008 Apr 2;3(4):e1927. doi: 10.1371/journal.pone.0001927.

43.

Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients.

van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Rustenburg F, Baggen JM, Verweij CL, Tak PP.

Ann Rheum Dis. 2008 Apr;67(4):563-6. Epub 2007 Nov 27.

PMID:
18042642
44.

Gene expression profiling in rheumatology.

van der Pouw Kraan TC, van Baarsen LG, Rustenburg F, Baltus B, Fero M, Verweij CL.

Methods Mol Med. 2007;136:305-27.

PMID:
17983157
45.

Expression of a pathogen-response program in peripheral blood cells defines a subgroup of rheumatoid arthritis patients.

van der Pouw Kraan TC, van Baarsen LG, Wijbrandts CA, Voskuyl AE, Rustenburg F, Baggen JM, Dijkmans BA, Tak PP, Verweij CL.

Genes Immun. 2008 Jan;9(1):16-22. Epub 2007 Oct 11.

PMID:
17928867
46.

CCL5 and CCR5 genotypes modify clinical, radiological and pathological features of multiple sclerosis.

van Veen T, Nielsen J, Berkhof J, Barkhof F, Kamphorst W, Bö L, Ravid R, Verweij CL, Huitinga I, Polman CH, Uitdehaag BM.

J Neuroimmunol. 2007 Oct;190(1-2):157-64. Epub 2007 Sep 19.

PMID:
17884183
47.
48.

Heritability of autistic traits in the general population.

Hoekstra RA, Bartels M, Verweij CJ, Boomsma DI.

Arch Pediatr Adolesc Med. 2007 Apr;161(4):372-7.

PMID:
17404134
49.

Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients.

van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Voskuyl AE, Rustenburg F, Baggen JM, Ibrahim SM, Fero M, Dijkmans BA, Tak PP, Verweij CL.

Ann Rheum Dis. 2007 Aug;66(8):1008-14. Epub 2007 Jan 12.

50.

A subtype of multiple sclerosis defined by an activated immune defense program.

van Baarsen LG, van der Pouw Kraan TC, Kragt JJ, Baggen JM, Rustenburg F, Hooper T, Meilof JF, Fero MJ, Dijkstra CD, Polman CH, Verweij CL.

Genes Immun. 2006 Sep;7(6):522-31. Epub 2006 Jul 13.

PMID:
16837931

Supplemental Content

Loading ...
Support Center